Journal of Cancer Immunology & Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Case Report - Journal of Cancer Immunology & Therapy (2019) Volume 2, Issue 1

Nocardiosis in cancer patients

Myelofibrosis is a serious bone marrow disorder that disrupts body's normal production of blood cells. The result is extensive scarring in bone marrow, leading to severe anaemia, weakness, fatigue and often an enlarged spleen. Myelofibrosis is an uncommon type of chronic leukaemia, a cancer that affects the blood-forming tissues in the body. It belongs to a group of diseases called myeloproliferative disorders. Many people with Myelofibrosis get progressively worse, and some may eventually develop a more serious form of leukaemia. Yet it's also possible to have Myelofibrosis and live symptom-free for years. Treatment for Myelofibrosis, which focuses on relieving symptoms, can involve a variety of options. Infections due to Nocardia spp are rare; localized skin forms are often seen among categories with limited exposure, such as agricultural workers. Although uncommon, disseminated infections are severe and life-threatening and affect mainly immunodeficient patients. The most common localization is the lung, but Central Nervous System (CNS), soft tissue, blood, and lymph nodes are also involved in disseminated Nocardiosis. Author(s): Parijat N Goswami, Harsha Panchal, Sonia Parikh, Hitesh Rajpara, Hemang Purohit

Abstract Full Text PDF

Get the App